Celgene and MBC BioLabs Announce 2019 Golden Ticket Competition
Celgene is awarding up to 2 Golden Tickets to promising, qualified entrepreneurs! With a strong commitment to delivering innovative and life-changing medicines, Celgene focuses on the discovery, development, and commercialization of products for the treatment of cancer, immune, neurodegenerative, and other severe conditions.
To apply,please email your non-confidential company presentation email@example.com Friday, August 16, 2019. In your presentation, please include:
How will a Golden Ticket impact your company's aims?
When would you like to start using the space?
A Golden Ticket provides one free lab bench and core facilities access at MBC BioLabs for one year. Celgene will notify the Golden Ticket finalists in September 2019.
Promega Sponsors MBC BioLabs
Promega has generously placed a GloMax® Discover Microplate Reader at MBC BioLabs San Francisco and San Carlos. This advanced plate reader provides flexible use of filters and includes high-performance luminescence, fluorescence, UV-Visible absorbance, BRET and FRET, two-color filtered luminescence and kinetic measurement capabilities.
Co-founder and CEO of Mammoth Biosciences on Fortune's 2019 40 Under 40
Mammoth Biosciences came to life at MBC BioLabs and now co-founder and CEO Trevor Martin has been been selected by Fortune as one of the most influential young people in business. Read Full Article.
Larger Than Life Science: Cybersecurity for Every Company
August 28, 2019 4:30 to 7:30 PM MBC BioLabs - 953 Indiana Street, San Francisco Drinks and appetizers served
Larger Than Life Science is a free monthly event series open to everyone interested in building a strong support network for life science and healthcare innovators. At this event, two cybersecurity experts will demystify the data breach and recommend best practices from technical and legal perspectives to avoid being hacked. Bring your questions for this interactive event. Join us for an evening of unconventional conversation!
Regencor Inc. is focused on developing a new therapy to regenerate the human heart after a heart attack. The therapy is delivered by existing standard of care coronary revascularization procedures. The Company has discovered that a hypo-glycosylated variant of the normal circulating human protein, Follistatin-Like 1 (hgFSTL-1), regenerates lost cardiac muscle and blood vessels, and significantly reduces scar volume when delivered to the adult mammalian heart after infarction.
ThinkCyte has built the Ghost Cytometry technology, the world's first high-throughput image-based cell sorting system by integrating advanced imaging, machine learning and microfluidics technologies. It enables researchers to identify cells based on their high content phenotypes (i.e. fluorescence and phase images) and isolate the target cells at high throughput, even without any labels. This innovative approach brings high-throughput, content-rich analysis and sorting on a single cell level to disciplines such as phenotypic drug screening and cell therapy.